...
首页> 外文期刊>Frontiers in Cell and Developmental Biology >Repression of CD24 surface protein expression by oncogenic Ras is relieved by inhibition of Raf but not MEK or PI3K
【24h】

Repression of CD24 surface protein expression by oncogenic Ras is relieved by inhibition of Raf but not MEK or PI3K

机译:通过抑制Raf可以缓解致癌Ras对CD24表面蛋白表达的抑制作用,但不能抑制MEK或PI3K

获取原文

摘要

CD24 is a dynamically regulated cell surface protein. High expression of CD24 leads to progression of lung, prostrate, colon and pancreatic cancers, among others. In contrast, low expression of CD24 leads to cell proliferation and metastasis of breast cancer stem cells (BCSCs). Activating mutations in Ras are found in 30% of all human cancers. Oncogenic Ras constitutively stimulates the Raf, PI3K and Ral GDS signaling pathways, leading to cellular transformation. Previous studies have shown that expression of oncogenic Ras in breast cancer cells generates CD24- cells from CD24+ cells. However, the molecular mechanisms involved in the generation of CD24- cells were not determined. Here, we demonstrate that oncogenic Ras (RasV12) expression suppresses CD24 mRNA, protein, and promoter levels when expressed in NIH/3T3 cells. Furthermore, activation of only the Raf pathway was sufficient to downregulate CD24 mRNA and protein expression to levels similar to those seen in with RasV12 expression. In contrast, activation of the PI3K pathway downregulated mRNA expression with a partial effect on protein expression whereas activation of the RalGDS pathway only partially affected protein expression. Surprisingly, inhibition of MEK with U0126 only partially restored CD24 mRNA expression but not surface protein expression. In contrast, inhibition of Raf with sorafenib did not restore CD24 mRNA expression but significantly increased the proportion of RasV12 cells expressing CD24. Therefore, the Raf pathway is the major repressor of CD24 mRNA and protein expression, with PI3K also able to substantially inhibit CD24 expression. Moreover, these data indicate that the levels of CD24 mRNA and surface protein are independently regulated. Although inhibition of Raf by sorafenib only partially restored CD24 expression, sorafenib should still be considered as a potential therapeutic strategy to alter CD24 expression in CD24- cells, such as BCSCs.
机译:CD24是动态调节的细胞表面蛋白。 CD24的高表达导致肺癌,前列腺癌,结肠癌和胰腺癌等疾病的进展。相反,CD24的低表达导致乳腺癌干细胞(BCSCs)的细胞增殖和转移。在所有人类癌症中,有30%发现了Ras的激活突变。致癌性Ras组成性地刺激Raf,PI3K和Ral GDS信号通路,从而导致细胞转化。先前的研究表明,乳腺癌细胞中致癌性Ras的表达从CD24 +细胞产生CD24-细胞。但是,尚未确定参与CD24细胞生成的分子机制。在这里,我们证明了当在NIH / 3T3细胞中表达时,致癌性Ras(RasV12)表达可抑制CD24 mRNA,蛋白质和启动子水平。此外,仅Raf途径的激活足以将CD24 mRNA和蛋白表达下调至与RasV12表达相似的水平。相反,PI3K途径的激活下调了mRNA表达,对蛋白质表达产生了部分影响,而RalGDS途径的激活仅部分影响了蛋白质表达。出人意料的是,用U0126抑制MEK仅部分恢复了CD24 mRNA表达,但未恢复表面蛋白表达。相反,用索拉非尼抑制Raf不能恢复CD24 mRNA的表达,但会显着增加表达CD24的RasV12细胞的比例。因此,Raf途径是CD24 mRNA和蛋白质表达的主要阻遏物,PI3K也能够基本上抑制CD24表达。此外,这些数据表明CD24 mRNA和表面蛋白的水平是独立调节的。尽管索拉非尼抑制Raf仅能部分恢复CD24的表达,但索拉非尼仍应被视为改变CD24细胞(如BCSC)中CD24表达的潜在治疗策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号